Advertisement
Advertisement

RDY

RDY logo

Dr. Reddy's Laboratories Limited - ADR

14.08
USD
Sponsored
+0.11
+0.82%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

14.20

+0.12
+0.82%

RDY Earnings Reports

Positive Surprise Ratio

RDY beat 23 of 40 last estimates.

57%

Next Report

Date of Next Report
May 07, 2026
Estimate for Q4 26 (Revenue/ EPS)
$87.12B
/
$13.54
Implied change from Q3 26 (Revenue/ EPS)
-0.48%
/
-6.75%
Implied change from Q4 25 (Revenue/ EPS)
+2.15%
/
-29.11%

Dr. Reddy's Laboratories Limited - ADR earnings per share and revenue

On Jan 21, 2026, RDY reported earnings of 14.52 USD per share (EPS) for Q3 26, beating the estimate of 13.86 USD, resulting in a 4.69% surprise. Revenue reached 87.53 billion, compared to an expected 85.48 billion, with a 2.40% difference. The market reacted with a +3.24% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 8 analysts forecast an EPS of 13.54 USD, with revenue projected to reach 87.12 billion USD, implying an decrease of -6.75% EPS, and decrease of -0.48% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Teva Pharmaceutical Industries Limited - ADR
Report Date
Jan 28, 2026 For Q4 25
Estimate
$0.69
Actual
$0.96
Surprise
+38.55%
FAQ
For Q3 2026, Dr. Reddy's Laboratories Limited - ADR reported EPS of $14.52, beating estimates by 4.69%, and revenue of $87.53B, 2.4% above expectations.
The stock price moved up 3.24%, changed from $13.28 before the earnings release to $13.71 the day after.
The next earning report is scheduled for May 07, 2026.
Based on 8 analysts, Dr. Reddy's Laboratories Limited - ADR is expected to report EPS of $13.54 and revenue of $87.12B for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement